Complete pathological remission and tertiary lymphoid structures are associated with the efficacy of resectable NSCLC receiving neoadjuvant chemoimmunotherapy: A double-center retrospective study

References

• Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–12. doi:10.3322/caac.21763.
   PubMed Web of Science ®Google Scholar
• Felip E, Rosell R, Maestre JA, Rodríguez-Paniagua JM, Morán T, Astudillo J, Alonso G, Borro JM, González-Larriba JL, Torres A, et al. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non–small-cell lung cancer. J Clin Oncol. 2010;28(19):3138–45. doi:10.1200/jco.2009.27.6204.
   PubMed Web of Science ®Google Scholar
• Zhang B, Zhong H, Han B. Neoadjuvant immunotherapy for patients with non-small cell lung cancer-is a new era coming? JAMA Oncol. 2023;9(3):301–2. doi:10.1001/jamaoncol.2022.6898.
   PubMed Web of Science ®Google Scholar
• Conroy M, Forde PM. Advancing neoadjuvant immunotherapy for lung cancer. Nat Med. 2023;29(3):533–4. doi:10.1038/s41591-023-02246-2.
   PubMedGoogle Scholar
• Provencio M, Nadal E, González-Larriba JL, Martínez-Martí A, Bernabé R, Bosch-Barrera J, Casal-Rubio J, Calvo V, Insa A, Ponce S, et al. Perioperative nivolumab and chemotherapy in stage III non–small-cell lung cancer. N Engl J Med. 2023;389:504–13. doi:10.1056/NEJMoa2215530.
   PubMed Web of Science ®Google Scholar
• Provencio M, Serna-Blasco R, Nadal E, Insa A, García-Campelo MR, Casal Rubio J, Dómine M, Majem M, Rodríguez-Abreu D, Martínez-Martí A, et al. Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage IIIA non–small-cell lung cancer (NADIM phase II trial). J Clin Oncol. 2022;40(25):2924–33. doi:10.1200/jco.21.02660.
   PubMed Web of Science ®Google Scholar
• Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973–85. doi:10.1056/NEJMoa2202170.
   PubMed Web of Science ®Google Scholar
• Heymach JV, Mitsudomi T, Harpole D, Aperghis M, Jones S, Mann H, Fouad TM, Reck M. Design and rationale for a phase III, Double-blind, placebo-controlled study of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab for the treatment of patients with resectable stages II and III non-small-cell lung cancer: the AEGEAN trial. Clin Lung Cancer. 2022;23(3):e247–e51. doi:10.1016/j.cllc.2021.09.010.
   PubMed Web of Science ®Google Scholar
• Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064–74. doi:10.1158/1078-0432.ccr-13-3271.
   PubMed Web of Science ®Google Scholar
• Yarchoan M, Hopkins A, Jaffee EM, Jaffee, EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377(25):2500–1. doi:10.1056/NEJMc1713444.
   PubMed Web of Science ®Google Scholar
• Sun X, Liu W, Sun L, Mo H, Feng Y, Wu X, Li C, Chen C, Li J, Xin Y, et al. Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer. J Immunother Cancer. 2022;10(11):e005531. doi:10.1136/jitc-2022-005531.
   PubMed Web of Science ®Google Scholar
• Sautès-Fridman C, Petitprez F, Calderaro J, Fridman WH. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 2019;19(6):307–25. doi:10.1038/s41568-019-0144-6.
   PubMed Web of Science ®Google Scholar
• Fridman WH, Meylan M, Petitprez F, Sun CM, Italiano A, Sautès-Fridman C. B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. Nat Rev Clin Oncol. 2022;19(7):441–57. doi:10.1038/s41571-022-00619-z.
   PubMed Web of Science ®Google Scholar
• Schumacher TN, Thommen DS. Tertiary lymphoid structures in cancer. Science ( New York, N.Y.). 2022;375(6576):eabf9419. doi: 10.1126/science.abf9419.
   PubMed Web of Science ®Google Scholar
• Cottrell TR, Thompson ED, Forde PM, Stein JE, Duffield AS, Anagnostou V, Rekhtman N, Anders RA, Cuda JD, Illei PB, et al. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann Oncol. 2018;29(8):1853–60. doi:10.1093/annonc/mdy218.
   PubMed Web of Science ®Google Scholar
• Tamiya Y, Nakai T, Suzuki A, Mimaki S, Tsuchihara K, Sato K, Yoh K, Matsumoto S, Zenke Y, Nosaki K, et al. The impact of tertiary lymphoid structures on clinicopathological, genetic and gene expression characteristics in lung adenocarcinoma. Lung Cancer ( Amsterdam, Netherlands). 2022;174:125–32. doi:10.1016/j.lungcan.2022.11.001.
   PubMed Web of Science ®Google Scholar
• Wakasu S, Tagawa T, Haratake N, Kinoshita F, Oku Y, Ono Y, Takenaka T, Oda Y, Shimokawa M, Mori M. Preventive effect of tertiary lymphoid structures on lymph node metastasis of lung adenocarcinoma. Cancer Immunol Immunother. 2023;72(6):1823–34. doi:10.1007/s00262-022-03353-8.
   PubMed Web of Science ®Google Scholar
• Cai W, Jing M, Gu Y, Bei T, Zhao X, Chen S, Wen J, Gao J, Wu C, Xue Z. Tumor microenvironment features decipher the outperformance of neoadjuvant immunochemotherapy over chemotherapy in resectable non-small cell lung cancer. Front Immunol. 2022;13:984666. doi:10.3389/fimmu.2022.984666.
   PubMed Web of Science ®Google Scholar
• Pataer A, Kalhor N, Correa AM, Raso MG, Erasmus JJ, Kim ES, Behrens C, Lee JJ, Roth JA, Stewart DJ, et al. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J Thorac Oncol. 2012;7(5):825–32. doi:10.1097/JTO.0b013e318247504a.
   PubMed Web of Science ®Google Scholar
• Posch F, Silina K, Leibl S, Mündlein A, Moch H, Siebenhüner A, Samaras P, Riedl J, Stotz M, Szkandera J, et al. Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer. Oncoimmunology. 2018;7(2):e1378844. doi:10.1080/2162402x.2017.1378844.
   PubMed Web of Science ®Google Scholar
• Felip E, Altorki N, Zhou C, Csőszi T, Vynnychenko I, Goloborodko O, Luft A, Akopov A, Martinez-Marti A, Kenmotsu H, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021;398(10308):1344–57. doi:10.1016/s0140-6736(21)02098-5. London, England.
   PubMed Web of Science ®Google Scholar
• Waser NA, Adam A, Schweikert B, Vo L, McKenna M, Breckenridge M, Penrod JR, Goring S. Pathologic response as early endpoint for survival following neoadjuvant therapy (NEO-AT) in resectable non-small cell lung cancer (rNSCLC): systematic literature review and meta-analysis. Ann Oncol. 2020;31:S806–S806. doi:10.1016/j.annonc.2020.08.116.
   Web of Science ®Google Scholar
• Petitprez F, de Reyniès A, Keung EZ, Chen TW, Sun CM, Calderaro J, Jeng YM, Hsiao LP, Lacroix L, Bougoüin A, et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature. 2020;577(7791):556–60. doi:10.1038/s41586-019-1906-8.
   PubMed Web of Science ®Google Scholar
• Lauss M, Donia M, Svane IM, Jönsson G. B cells and tertiary lymphoid structures: friends or foes in cancer immunotherapy? Clin Cancer Res. 2022;28(9):1751–8. doi:10.1158/1078-0432.ccr-21-1130.
   PubMed Web of Science ®Google Scholar
• Vanhersecke L, Brunet M, Guégan JP, Rey C, Bougouin A, Cousin S, Moulec SL, Besse B, Loriot Y, Larroquette M, et al. Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nat Cancer. 2021;2(8):794–802. doi:10.1038/s43018-021-00232-6.
   PubMedGoogle Scholar
• Väyrynen JP, Sajanti SA, Klintrup K, Mäkelä J, Herzig KH, Karttunen TJ, Tuomisto A, Mäkinen MJ. Characteristics and significance of colorectal cancer associated lymphoid reaction. Int J Cancer. 2014;134(9):2126–35. doi:10.1002/ijc.28533.
   PubMed Web of Science ®Google Scholar
• Ueno H, Hashiguchi Y, Shimazaki H, Shinto E, Kajiwara Y, Nakanishi K, Kato K, Maekawa K, Miyai K, Nakamura T, et al. Objective criteria for crohn-like lymphoid reaction in colorectal cancer. Am J Clin Pathol. 2013;139(4):434–41. doi:10.1309/ajcpwhueftgbwke4.
   PubMed Web of Science ®Google Scholar
• Fukuhara M, Muto S, Inomata S, Yamaguchi H, Mine H, Takagi H, Ozaki Y, Watanabe M, Inoue T, Yamaura T, et al. The clinical significance of tertiary lymphoid structure and its relationship with peripheral blood characteristics in patients with surgically resected non-small cell lung cancer: a single-center, retrospective study. Cancer Immunol Immunother. 2022;71(5):1129–37. doi:10.1007/s00262-021-03067-3.
   PubMed Web of Science ®Google Scholar
• Goc J, Germain C, Vo-Bourgais TK, Lupo A, Klein C, Knockaert S, de Chaisemartin L, Ouakrim H, Becht E, Alifano M, et al. Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. Cancer Res. 2014;74(3):705–15. doi:10.1158/0008-5472.can-13-1342.
   PubMed Web of Science ®Google Scholar
• Brunet M, Crombé A, Cousin S, Vanhersecke L, Le Loarer F, Bessede A, Italiano A. Mature tertiary lymphoid structure is a specific biomarker of cancer immunotherapy and does not predict outcome to chemotherapy in non-small-cell lung cancer. Ann Oncol. 2022;33(10):1084–5. doi:10.1016/j.annonc.2022.06.007.
   PubMed Web of Science ®Google Scholar
• Remark R, Lupo A, Alifano M, Biton J, Ouakrim H, Stefani A, Cremer I, Goc J, Régnard JF, Dieu-Nosjean MC, et al. Immune contexture and histological response after neoadjuvant chemotherapy predict clinical outcome of lung cancer patients. Oncoimmunology. 2016;5(12):e1255394. doi:10.1080/2162402x.2016.1255394.
   PubMed Web of Science ®Google Scholar
• Siliņa K, Soltermann A, Attar FM, Casanova R, Uckeley ZM, Thut H, Wandres M, Isajevs S, Cheng P, Curioni-Fontecedro A, et al. Germinal centers determine the prognostic relevance of tertiary lymphoid structures and are impaired by corticosteroids in lung squamous cell carcinoma. Cancer Res. 2018;78(5):1308–20. doi:10.1158/0008-5472.can-17-1987.
   PubMed Web of Science ®Google Scholar
• Chaft JE, Oezkan F, Kris MG, Bunn PA, Wistuba II, Kwiatkowski DJ, Owen DH, Tang Y, Johnson BE, Lee JM, et al. Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial. Nat Med. 2022;28(10):2155–61. doi:10.1038/s41591-022-01962-5.
   PubMed Web of Science ®Google Scholar
• Deutsch JS, Cimino-Mathews A, Thompson E, Provencio M, Forde PM, Spicer J, Girard N, Wang D, Anders RA, Gabrielson E, et al. Association between pathologic response and survival after neoadjuvant therapy in lung cancer. Nat Med. 2023. doi:10.1038/s41591-023-02660-6.
   Web of Science ®Google Scholar